Morphic Holding, Inc.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF…
Biotechnology
US, Waltham [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -7.15 | -30.09 | -28.09 | |
| Graham Fair Price | 2.35 | 16.44 | 16.07 | |
| PEG | -15.73 | -0.83 | -0.72 | |
| Price/Book | 20.33 | 2.48 | 2.06 | |
| Price/Cash Flow | 30.22 | -34.97 | -50.12 | |
| Prices/Earnings | -3.02 | -9.08 | -8.82 | |
| Price/Sales | inf | 0.00 | -23.85 | |
| Price/FCF | 30.22 | -34.97 | -50.12 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | inf | 0.00 | 1.00 | |
| Operating Margin | inf | 0.00 | 0.82 | |
| ROA | -17.67 | -0.07 | -0.06 | |
| ROE | -0.06 | -0.07 | -16.80 | |
| ROIC | -0.07 | -0.08 | -13.57 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.40 | -0.14 | 182.72 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.10 | -0.08 | 19.33 | |
| EPS QOQ | -0.12 | -0.11 | 10.98 | |
| FCF QOQ | 0.03 | -0.64 | 2035.79 | |
| Revenue QOQ | 0.00 | 1.00 | 100.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | < 0.005 | < 0.005 | 46.80 | |
| Quick Ratio | 28.43 | 37.20 | 30.84 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 14.01 | 13.27 | -5.30 | |
| Cash | 14.16 | 13.17 | -6.96 | |
| Capex | < 0.005 | -0.01 | -620.94 | |
| Free Cash Flow | -0.58 | -0.94 | -63.31 | |
| Revenue | -1.21 | 0.00 | inf | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad